Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions

被引：0
|
作者：
Zeidan, Amer M. [1 ,2 ]
Zhu, Weiwei [2 ]
Wang, Rong [3 ,4 ]
Stahl, Maximilian [1 ,2 ]
Huntington, Scott F. [3 ,5 ]
Giri, Smith [3 ,6 ]
Podoltsev, Nikolai A. [1 ,2 ]
Gore, Steven D. [1 ,3 ]
Ma, Xiaomei [2 ,4 ]
Davidoff, Amy J. [3 ,7 ]
机构：
[1] Yale Sch Med, Sect Hematol, Dept Internal Med, New Haven, CT USA
[2] Yale Sch Med, Yale Canc Outcomes Publ Policy & Effectiveness Re, New Haven, CT USA
[3] Yale Univ, Sch Med, Yale Canc Outcomes Publ Policy & Effectiveness Re, New Haven, CT USA
[4] Yale Univ, Yale Sch Publ Hlth, Dept Chron Dis, New Haven, CT USA
[5] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06510 USA
[6] Yale Univ, Sch Med, Sect Hematol, New Haven, CT USA
[7] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-116497
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
838
引用
收藏
页数：3
相关论文
共 49 条
  • [21] Luspatercept Versus Epoetin Alfa for Treatment (Tx) of Anemia in Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients (pts) Requiring RBC Transfusions (RBCT): Data from the Phase 3 COMMANDS Study
    Platzbecker, U.
    Della Porta, M. G.
    Santini, V.
    Zeidan, A. M.
    Fenaux, P.
    Komrokji, R. S.
    Shortt, J.
    Valcarcel, D.
    Jonasova, A.
    Dimicoli-Salazar, S.
    Tiong, I. S.
    Lin, C. -C.
    Li, J.
    Zhang, J.
    Giuseppi, A. C.
    Kreitz, S.
    Pozharskaya, V.
    Keeperman, K. L.
    Rose, S.
    Shetty, J. K.
    Hayati, S.
    Vodala, S.
    Degulys, A.
    Paolini, S.
    Cluzeau, T.
    Garcia-Manero, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 16 - 17
  • [22] IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).
    Zeidan, Amer Methqal
    Platzbecker, Uwe
    Santini, Valeria
    Fenaux, Pierre
    Sekeres, Mikkael A.
    Savona, Michael R.
    Madanat, Yazan F.
    Diez-Campelo, Maria
    Valcarcel, David
    Illmer, Thomas
    Jonasova, Anna
    Belohlavkova, Petra
    Sherman, Laurie Jill
    Berry, Tymara
    Dougherty, Souria
    Shah, Sheetal
    Sun, Libo
    Wan, Ying
    Huang, Fei
    Komrokji, Rami S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Clinical outcomes and healthcare resource utilization (HCRU) in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) reinitiating erythropoiesis-stimulating agents (ESAs) following previous ESA treatment.
    Garcia-Manero, Guillermo
    Matsuno, Rayna K.
    McBride, Ali
    Brown, Thomas D.
    Idryo, Danny
    Broome, Ronda
    Herriman, Autumn
    Johnson, Tiffany
    Wilkinson, Kristiana
    Walters, Sheetal
    Schrag, Andrew
    Johanson, Colden
    Izano, Monika A.
    Mukherjee, Sudipto
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Luspatercept Reduces Red Blood Cell Transfusions (RBCT) in Patients with Lower-Risk Myelodysplastic Syndromes (LRMDS) Regardless of Baseline Transfusion Burden (TB) in the MEDALIST Study
    Platzbecker, Uwe
    Garcia-Manero, Guillermo
    Fenaux, Pierre
    Buckstein, Rena
    Santini, Valeria
    Diez-Campelo, Maria
    Tang, Derek
    Ito, Rodrigo
    Fabre, Shannon
    Mantovani, Emily
    Zoffoli, Roberto
    Miteva, Dimana
    Hughes, Christina
    Khan, Wasiulla
    Komrokji, Rami S.
    Germing, Ulrich
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 142 - 142
  • [25] Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial
    Platzbecker, Uwe
    Dunshee, Diana
    Komrokji, Rami S.
    Mufti, Ghulam J.
    Garcia-Manero, Guillermo
    Buckstein, Rena
    Santini, Valeria
    Diez-Campelo, Maria
    Sekeres, Mikkael A.
    See, Wendy L.
    Tsai, Kevin
    Risueno, Alberto
    Ma, Jianglin
    Schwickart, Martin
    Rampersad, Anita
    Zhang, Jennie
    Laadem, Abderrahmane
    Menezes, Daniel
    MacBeth, Kyle
    Linde, Peter G.
    Reynolds, Joseph G.
    List, Alan F.
    Fenaux, Pierre
    BLOOD, 2019, 134
  • [26] Association of Clinical Characteristics at Diagnosis with Outcomes in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from a Real-World Medical Chart Review in the US
    Mukherjee, Sudipto
    Savill, Kristin M.
    Gajra, Ajeet
    Gentile, Danielle
    Falkenstein, Angelica
    Miller, Talia
    Laney, JaLyna
    McBride, Ali
    BLOOD, 2022, 140 : 10998 - 11000
  • [27] Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
    Santini, Valeria
    Almeida, Antonio
    Giagounidis, Aristoteles
    Groepper, Stefanie
    Jonasova, Anna
    Vey, Norbert
    Mufti, Ghulam J.
    Buckstein, Rena
    Mittelman, Moshe
    Platzbecker, Uwe
    Shpilberg, Ofer
    Ram, Ron
    del Canizo, Consuelo
    Gattermann, Norbert
    Ozawa, Keiya
    Risueno, Alberto
    MacBeth, Kyle J.
    Zhong, Jianhua
    Seguy, Francis
    Hoenekopp, Albert
    Beach, C. L.
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2988 - +
  • [28] Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB)
    Henry, David H.
    Glaspy, John
    Harrup, Rosemary Anne
    Mittelman, Moshe
    Zhou, Amy
    Bradley, Charles
    Saha, Gopal
    Bartels, Pamela
    Robert, Leong
    Yu, Kin-Hung P.
    BLOOD, 2019, 134
  • [29] CLINICAL BENEFIT AMONG LENALIDOMIDE (LEN)-TREATED PATIENTS (PTS) WITH RBC TRANSFUSION-DEPENDENT (RBC-TD) LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT DEL(5Q)
    Garcia-Manero, G.
    Almeida, A.
    Fenaux, P.
    Gattermann, N.
    Giagounidis, A.
    Goldberg, S.
    Ozawa, K.
    Weaver, J.
    Sugrue, M. M.
    Santini, V.
    HAEMATOLOGICA, 2016, 101 : 72 - 73
  • [30] Clinical benefit among lenalidomide (LEN)-treated patients (pts) with RBC transfusion-dependent (RBC-TD) low-/int-1-risk myelodysplastic syndromes (MDS) without del(5q).
    Garcia-Manero, Guillermo
    Almeida, Antonio Medina
    Fenaux, Pierre
    Gattermann, Norbert
    Giagounidis, Aristoteles
    Goldberg, Stuart
    Ozawa, Keiya
    Weaver, Jerry
    Sugrue, Mary M.
    Santini, Valeria
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345